Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 4
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 3(1)
Phase 4(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05361369Phase 1Completed

Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

Role: lead

NCT06056947Phase 3Completed

Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule

Role: collaborator

NCT03839875Phase 4Completed

Evaluation of Efficacy and Safety of Gynomax® XL Ovule

Role: lead

All 3 trials loaded